HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Cutaneous Mastocytosis

Subscribe to New Research on Cutaneous Mastocytosis

Skin lesions due to abnormal infiltration of MAST CELLS. Cutaneous mastocytosis is confined to the skin without the involvement of other tissues or organs, and is mostly found in children. The three major variants are: URTICARIA PIGMENTOSA; diffuse cutaneous mastocytosis; and SOLITARY MASTOCYTOMA OF SKIN.

Also Known As:

Mastocytosis, Cutaneous; Bullous Mastocytoses; Bullous Mastocytosis; Cutaneous Mastocytoses; Cutaneous Mastocytoses, Diffuse; Cutaneous Mastocytosis, Diffuse; Mastocytoses, Bullous; Mastocytoses, Cutaneous; Mastocytoses, Skin; Mastocytosis, Skin; Skin Mastocytoses; Mastocytosis, Bullous; Mastocytosis, Diffuse Cutaneous; Skin Mastocytosis

Networked: 83 relevant articles (4 outcomes, 5 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Mastocytosis (Mast-Cell Disease)
2.	Hypereosinophilic Syndrome (Loeffler Endocarditis)
3.	Urticaria Pigmentosa
4.	Systemic Mastocytosis
5.	Blister (Bulla)

Experts

1.	Brockow, K: 3 articles (07/2015 - 02/2008)
2.	Dubreuil, Patrice: 2 articles (01/2013 - 12/2010)
3.	Ma, Zhongcai: 2 articles (11/2011 - 01/2010)
4.	van Toorenenbergen, A W: 2 articles (06/2009 - 09/2002)
5.	Oranje, A P: 2 articles (06/2009 - 09/2002)
6.	Heide, R: 2 articles (06/2009 - 09/2002)
7.	Tank, B: 2 articles (06/2009 - 09/2002)
8.	Zanotti, R: 1 article (07/2015)
9.	Mosbech, H: 1 article (07/2015)
10.	Bonadonna, P: 1 article (07/2015)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Cutaneous Mastocytosis:

1.	VenomsIBA 05/01/2014 - "In addition, we report the case of a patient at high risk and with cutaneous mastocytosis, whose symptoms improved with concomitant administration of omalizumab and venom immunotherapy. " 08/01/2006 - "Venom immunotherapy was found to be marginally less effective in patients with mastocytosis than in those without evidence of mast cell disease (defined as absent cutaneous mastocytosis combined with a serum tryptase concentration of <11.4 microg/l). "
2.	Tryptases (Tryptase)IBA 06/01/2015 - "No abnormalities in the laboratory tests were found except for a serum tryptase level (STL) of 11.8 ng/ml. The histological and immunohistochemical examinations confirmed the diagnosis of cutaneous mastocytosis. " 10/01/2007 - "Expression of tryptase, CD25, CD2 and pSTAT5 was evaluated by immunohistochemistry (IHC) on archival cases of SM and cutaneous mastocytosis (CM). " 07/01/2015 - "Nevertheless, clonal MC disorders should be ruled out in cases of severe anaphylaxis: basal serum tryptase determination, physical examination for cutaneous mastocytosis lesions, and clinical characteristics of anaphylactic reaction might be useful for differential diagnosis. " 06/01/2009 - "Serum tryptase and SCORMA (SCORing MAstocytosis) Index as disease severity parameters in childhood and adult cutaneous mastocytosis." 04/01/2004 - "In all cases the lesional mast cells expressed SERPINB6, and, in diffuse cutaneous mastocytosis and mastocytoma, SERPINB6 was expressed by a substantially higher number of mast cells when compared with tryptase. "
3.	imatinib (Gleevec)FDA Link 01/01/2013 - "Imatinib mesylate in the treatment of diffuse cutaneous mastocytosis." 09/01/2008 - "Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation." 08/01/2013 - "Symptomatic response to imatinib mesylate in cutaneous mastocytosis associated with chronic myelomonocytic leukemia." 08/01/2003 - "[Complete remission with imatinib mesylate (Glivec) of an idiopathic hypereosinophilic syndrome associated with a cutaneous mastocytosis after failure of interferon-alpha]."
4.	omalizumab (Xolair)FDA Link 11/01/2013 - "Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis." 05/01/2014 - "In addition, we report the case of a patient at high risk and with cutaneous mastocytosis, whose symptoms improved with concomitant administration of omalizumab and venom immunotherapy. "
5.	Interferon-alpha (Interferon Alfa)FDA Link 08/01/2003 - "[Complete remission with imatinib mesylate (Glivec) of an idiopathic hypereosinophilic syndrome associated with a cutaneous mastocytosis after failure of interferon-alpha]."
6.	fluticasone (Cutivate)FDA LinkGeneric 01/01/2007 - "Efficacy of 25% diluted fluticasone propionate 0.05% cream as wet-wrap treatment in cutaneous mastocytosis." 01/01/2007 - "25% dilution of fluticasone propionate 0.05% cream under wet-wrap occlusion is an alternative treatment modality for alleviating the symptoms of cutaneous mastocytosis, but the improvement may be moderate and fall short of the patient's expectations."
7.	AntibodiesIBA 01/01/2013 - "Expression of the basophil-specific antibodies 2D7 and BB1 in patients with cutaneous Mastocytosis." 01/01/2013 - "Using the antibodies 2D7, BB1, and c-Kit, we performed an immunohistochemical study of skin biopsy specimens from patients with cutaneous mastocytosis (15 urticaria pigmentosa and telangiectatic macularis eruptive perstans) and liver or bone marrow biopsy specimens from patients with systemic mastocytosis. " 07/08/2009 - "Immunohistochemistry and dual immunofluorescence using anti-tryptase and anti-capthepsin-G antibodies was performed on biopsy specimens from 20 cases diagnosed as cutaneous mastocytosis. " 08/01/1995 - "In order to evaluate its possible role in human mastocytosis, skin lesions from 13 patients with urticaria pigmentosa and five patients with mastocytomas, and normal skin specimens from five healthy donors were studied by immunohistochemistry, using polyclonal and monoclonal (hkl-12) antibodies against stem cell factor, and a monoclonal antibody (YB5.B8) against its receptor, the c-kit proto-oncogene product. "
8.	Cathepsin GIBA 07/08/2009 - "The aim of this study was to investigate the immunoreactivity to tryptase and to cathepsin-G of MC from human cutaneous mastocytosis and to compare their number in normal skin and cutaneous mastocytosis. " 07/08/2009 - "Morphometric evaluation of MC number demostrated that the number of both tryptase- and cathepsin-G-positive MC was significantly higher in cutaneous mastocytosis as compared to normal skin and that in both conditions the number of tryptase-positive MC was significantly higher as compared to the number of cathepsin-G-positive MC. " 07/08/2009 - "In conclusion, in this study, for the first time we have demonstrated the presence of MC with immunoreactivity to cathepsin-G in human cutaneous mastocytosis, as well as the co-localization of tryptase and cathepsin-G in MC secretory granules." 07/08/2009 - "Co-localization of tryptase and cathepsin-G in mast cells in cutaneous mastocytosis."
9.	Clobetasol (Clobetasol Propionate)FDA LinkGeneric 01/01/2010 - "Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial."
10.	Carbon MonoxideIBA 07/08/2009 - "In conclusion, in this study, for the first time we have demonstrated the presence of MC with immunoreactivity to cathepsin-G in human cutaneous mastocytosis, as well as the co-localization of tryptase and cathepsin-G in MC secretory granules." 07/08/2009 - "Co-localization of tryptase and cathepsin-G in mast cells in cutaneous mastocytosis."

Therapies and Procedures

1.	Immunotherapy 05/01/2014 - "In addition, we report the case of a patient at high risk and with cutaneous mastocytosis, whose symptoms improved with concomitant administration of omalizumab and venom immunotherapy. " 08/01/2006 - "Venom immunotherapy was found to be marginally less effective in patients with mastocytosis than in those without evidence of mast cell disease (defined as absent cutaneous mastocytosis combined with a serum tryptase concentration of <11.4 microg/l). "
2.	Photochemotherapy (Photodynamic Therapy) 12/01/1990 - "Photochemotherapy of dominant, diffuse, cutaneous mastocytosis." 01/01/2005 - "Diffuse cutaneous mastocytosis treated with psoralen photochemotherapy: case report and review of the literature." 02/01/2002 - "Skin-targeted therapies that lead to a resolution of the lesions of cutaneous mastocytosis are psoralen-photochemotherapy and topical corticosteroid therapy either by occlusion or intralesional injection for a limited number of lesions. "
3.	Radiotherapy 01/01/2009 - "Cutaneous mastocytosis localized to a radiotherapy field." 11/01/2013 - "We demonstrate a rare clinical presentation of cutaneous mastocytosis that occurred at the site of radiotherapy and then extended beyond this boundary, and ask whether this can be treated as a localised side effect of radiotherapy or whether the potential for systemic mastocytosis needs to be excluded. " 11/01/2013 - "Cutaneous mastocytosis extending beyond a radiotherapy site: a form of radiodermatitis or a neoplastic phenomenon?"
4.	Anesthesia 02/01/2005 - "We report the case of a patient diagnosed with cutaneous mastocytosis who underwent testicular biopsy with intradural anesthesia. " 01/01/1993 - "[Anesthesia of a child with a cutaneous mastocytosis]."
5.	Solid-State Lasers 06/01/2005 - "The diode-pumped Nd:YAG laser at 532 nanometers should be considered part of a dermatologist's armamentarium for the treatment of a patient's cosmetic concerns with lesions of cutaneous mastocytosis."